Fore Pharma, Jan 2012, Pages: 13
Fore Pharma’s latest report ‘Global OvarianCancerDrugPipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global ovariancancerdrug
Fore Pharma, Aug 2011, Pages: 13
Fore Pharma’s latest report ‘Global OvarianCancerDrugPipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global ovariancancerdrug
Jain PharmaBiotech, Feb 2012, Pages: 639
to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovariancancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer
Datamonitor, July 2010, Pages: 93
-Examination of the late-phase ovariancancerpipeline, including drug profiles of late-stage agents
-Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights
GlobalData, Sep 2011, Pages: 36
in seven major markets
- Obtain sales forecast for currently marketed/pipelinedrug for 2011-2020 for all seven major markets
Keywords
Paclitaxel, ovariancancer, Taxol, first and second line treatment
GlobalData, Jan 2012, Pages: 32
performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipelinedrug for 2011-2020 for all seven major markets
Keywords
Doxil, Caelyx, ovariancancer, doxorubicin
GBI Research, Dec 2011, Pages: 215
, ovariancancer, cervical cancer and head and neck cancer. The report also includes insights into the oncology therapeutics R&D pipeline. It analyzes the competitive landscape in the oncology therapeutics
GlobalData, Dec 2010, Pages: 55
OvarianCancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “OvarianCancer Therapeutics
Datamonitor, Jan 2011, Pages: 266
-specific assumptions Segmentation and analysis of the current breast and ovariancancerpipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer
GBI Research, March 2011, Pages: 120
include colorectal cancer, prostate cancer, head and neck cancer and ovariancancer. The report includes analysis of endpoints of major oncological market products and profiles. In addition to marketed
GBI Research, Feb 2011, Pages: 209
, Global, Early Stage R&D Pipeline by Phase in Melanoma, December 2010
Table 32: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of OvarianCancer, December 2010
Table 33: Drug
Life Science Analytics, March 2011, Pages: 656
OvarianCancer Therapy Area PipelineReport contains detailed information on the ovariancancerdrugpipeline. This report provides insight into the pipeline status of ovariancancerdrugs
Business Insights, June 2011, Pages: 164
The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents
Bioseeker, Oct 2010, Pages: 659
the cancer vaccine pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of cancer vaccine drugs is split between the 46% which
Bioseeker, Nov 2010, Pages: 777
to stratify the melanoma pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of melanoma drugs is split between the 55% which
Jain PharmaBiotech, Feb 2012, Pages: 864
biomarkers
Metabolomic biomarkers of cancer
Choline phospholipid biomarkers of cancer
Hypoxia-inducible factor-1
Detection of drug resistance in cancer by metabolic profiling
Epitomics for the early
GBI Research, Jan 2012, Pages: 118
Clinical Trials
5.6.3 Secondary Endpoints used in OvarianCancer Clinical Trials
5.6.4 Major Marketed Drugs-Safety and Efficacy Analysis
5.6.5 Phase III Clinical Trial Analysis
5.6.6 Phase III Primary
GBI Research, Feb 2011, Pages: 209
, Global, Early Stage R&D Pipeline by Phase in Melanoma, December 2010 166
Table 32: Early Stage Drug Discovery in Disease Segments, Global, Staging of OvarianCancer, December 2010 171
Table 33: Early Stage
Business Insights, Feb 2007, Pages: 105
-generation drug targets.
Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success
